Skip to content

Study · Randomized controlled trial · n = 122 · 1999

8 results

Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial.

Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH

Lancet (London, England)1 Jul 1999Cited by 76 (Europe PMC)

PMID10408485 (opens in a new tab)DOI10.1016/s0140-6736(98)12494-7 (opens in a new tab)PepBankPUB-10408485
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery, intensive-care clot ratios were higher with desmopressin than with placebo.

    In plain wordsIn cardiac surgery patients with abnormal clot tests, clot ratios were higher with desmopressin than with placebo.

    Peptide
    Desmopressin
    Outcome
    IncreaseClot ratio
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    P value
    0.0001 none
    clot ratio, placebo group lower than desmopressin and untreated control groups, intensive care

    Source sentences

    Summary
    In intensive care, clot ratios in patients who received desmopressin were similar to those in the untreated control group, despite significantly lower platelet counts, but were lower in the placebo group than in the other two groups (p=0.0001).
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery, 24-h blood loss was 624 mL with desmopressin versus 1028 mL with placebo (p=0.0004).

    In plain wordsIn cardiac surgery patients with abnormal clot tests, desmopressin reduced 24-hour blood loss compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseBlood loss at 24 h
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Bleeding · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean blood loss in 24 h, desmopressin
    624 mL
    desmopressin
    SD of blood loss in 24 h, desmopressin
    209 mL
    desmopressin
    Mean blood loss in 24 h, placebo
    1028 mL
    placebo
    SD of blood loss in 24 h, placebo
    682 mL
    placebo
    P value
    0.0004 none
    blood loss in 24 h, desmopressin versus placebo

    Source sentences

    Summary
    Compared with the placebo group, patients who received desmopressin had less blood loss in 24 h (mean 624 [SD 209] vs 1028 mL [682] p=0.0004)
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery, red cell transfusion was 1.1 U with desmopressin versus 2.2 U with placebo (p=0.009).

    In plain wordsIn cardiac surgery patients with abnormal clot tests, desmopressin reduced red cell transfusion compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseRed blood cell transfusion
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Transfusion · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean red blood cell transfusion, desmopressin
    1.1 U
    desmopressin
    Mean red blood cell transfusion, placebo
    2.2 U
    placebo
    SD of red blood cell transfusion, placebo
    0.32 U
    placebo
    P value
    0.009 none
    red blood cell transfusion, desmopressin versus placebo

    Source sentences

    Summary
    and required less transfusion of red blood cells (1.1 [022] vs 2.2 U [0.32] p=0.009)
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery, platelet transfusion was 0.1 U with desmopressin versus 1.9 U with placebo (p=0.0001).

    In plain wordsIn cardiac surgery patients with abnormal clot tests, desmopressin reduced platelet transfusion compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreasePlatelet transfusion
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Transfusion · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean platelet transfusion, desmopressin
    0.1 U
    desmopressin
    SD of platelet transfusion, desmopressin
    0.04 U
    desmopressin
    Mean platelet transfusion, placebo
    1.9 U
    placebo
    SD of platelet transfusion, placebo
    4.5 U
    placebo
    P value
    0.0001 none
    platelet transfusion, desmopressin versus placebo

    Source sentences

    Summary
    platelets (0.1 [0.04] vs 1.9 U [4.5] p=0.0001)
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery, plasma transfusion was 0.1 U with desmopressin versus 0.75 U with placebo (p=0.0008).

    In plain wordsIn cardiac surgery patients with abnormal clot tests, desmopressin reduced plasma transfusion compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseFresh-frozen plasma transfusion
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Transfusion · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean fresh-frozen plasma transfusion, desmopressin
    0.1 U
    desmopressin
    SD of fresh-frozen plasma transfusion, desmopressin
    0.07 U
    desmopressin
    Mean fresh-frozen plasma transfusion, placebo
    0.75 U
    placebo
    SD of fresh-frozen plasma transfusion, placebo
    0.21 U
    placebo
    P value
    0.0008 none
    fresh-frozen plasma transfusion, desmopressin versus placebo

    Source sentences

    Summary
    and fresh-frozen plasma (0.1 [0.07] vs 0.75 U [0.21] p=0.0008)
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery, donor exposures were 1.56 with desmopressin versus 5.2 with placebo (p=0.0001).

    In plain wordsIn cardiac surgery patients with abnormal clot tests, desmopressin reduced donor exposures compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseBlood-donor exposures
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Transfusion · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean total blood-donor exposures, desmopressin
    1.56 exposures
    desmopressin
    SD of total blood-donor exposures, desmopressin
    0.31 exposures
    desmopressin
    Mean total blood-donor exposures, placebo
    5.2 exposures
    placebo
    SD of total blood-donor exposures, placebo
    0.8 exposures
    placebo
    P value
    0.0001 none
    total blood-donor exposures, desmopressin versus placebo

    Source sentences

    Summary
    and had less total blood-donor exposures (1.56 [0.31] vs 5.2 [0.8] p=0.0001).
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  7. 07HumanNon-randomized trialEfficacy outcome

    In intensive care, clot ratios in patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery given desmopressin were similar to those in untreated controls with normal clot ratios.

    In plain wordsIn cardiac surgery patients with abnormal clot tests, clot ratios with desmopressin were similar to untreated patients with normal clot tests.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedClot ratio versus untreated controls
    Study

    n = 122

    Comparator
    Untreated controls
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In intensive care, clot ratios in patients who received desmopressin were similar to those in the untreated control group, despite significantly lower platelet counts, but were lower in the placebo group than in the other two groups (p=0.0001).
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
  8. 08HumanNon-randomized trialOther

    In intensive care, platelet counts were significantly lower in patients with abnormal hemoSTATUS clot ratios after bypass in cardiac surgery given desmopressin than in untreated controls with normal clot ratios.

    In plain wordsIn intensive care, platelet counts were lower in cardiac surgery patients with abnormal clot tests given desmopressin than in untreated patients with normal clot tests.

    Peptide
    Desmopressin
    Outcome
    DecreasePlatelet count
    Study

    n = 122

    Comparator
    Untreated controls
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In intensive care, clot ratios in patients who received desmopressin were similar to those in the untreated control group, despite significantly lower platelet counts, but were lower in the placebo group than in the other two groups (p=0.0001).
    2 context sentences
    Summary · context
    We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial.
    Summary · context
    Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07179991

DDAVP Effect by TEG6 in Cardiac Surgery

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sn = 1001 Aug 2026 to est. 31 Dec 2028

Intraoperative Bleeding

Trial pageClinicalTrials.govUpdated 21 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.